RxDoctor Payments Data

Anjeanette Brown, MD

Surgical Oncology · Cape May Court House, NJNPI 1982872016

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.5%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Endomagnetics Ltd at 58.6% of the total. Reporting peaked in 2022 at $5,776 and has fallen 72.1% since, to $1,610 in 2025. Among surgical oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,272in general payments, 2019–2025

Across 58 payments — averaging $194.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endomagnetics Ltd$7K
  • Musculoskeletal Transplant Foundation Inc.$2K
  • Dilon Technologies, Inc.$1K
  • Stryker$757
  • Elucent Medical$484
  • Medtronic$316
  • plus $555 from 10 others

What the payments were for

  • Travel & lodging$4,39639%
  • Food & beverage$6,59759%
  • Entertainment$2792%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,272 in reported general payments places this provider in the 90th percentile of 59 surgical oncology providers in New Jersey.

See all surgical oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$106,125
Medicare patients
283
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tramadol Hcl37$62

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Cape May Court House

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →